SOURCE: I-many, Inc.

April 18, 2008 08:13 ET

I-many Extends Subscription Agreement With Major Pharmaceutical Company

Mid Six-Figure Agreement Extends Relationship for Three More Years

EDISON, NJ--(Marketwire - April 18, 2008) - I-many, Inc. (NASDAQ: IMNY), a leading provider of contract management software and services for the enterprise, announced today a major pharmaceutical company has extended its subscription agreement with I-many for the use of I-many CARS® NG, I-many Medicaid Rebates™, and I-many Government Pricing™.

The agreement was extended an additional three years and is valued in the mid-six figures. This leading pharmaceutical company is yet another customer that has demonstrated its commitment to I-many and its comprehensive contract management solution.

"We are always pleased to win new business, or, in this case, to have a customer extend its contractual relationship with us," said John Rade, president and CEO of I-many. "New business demonstrates that we can compete and win against others in our markets. Contract extensions demonstrate customer loyalty and shows existing customers are satisfied with our services and products. Typically, we wait to report the details of unnamed sales in our quarterly earnings press release. However, since this is one of the agreements we had worked to complete in the first quarter, in the interest of transparency we are reporting it now. We plan to report on others as they come to fruition."

The I-many Contract Management Suite for Life Sciences manages hundreds of billions of dollars in corporate contracts, revenue and pricing agreements for life sciences companies. This solution directly addresses the challenges faced by life sciences companies as they navigate the complex regulatory environment.

About I-many®

I-many (NASDAQ: IMNY) is the leading provider of contract management software and services for the enterprise. With hundreds of customers across 21 industries worldwide, I-many is enabling businesses to manage the entire contract life cycle, from pre-contract processes and contract management to active compliance and contract optimization. The result is an end-to-end solution that provides greater levels of insight into contract performance, allowing companies to improve profitability and achieve a measurable return on investment. For more information, please visit

This news release contains forward-looking statements, and actual results may vary from those expressed or implied herein. Factors that could affect these results include the risk of unforeseen technical or practical impediments to planned software development and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission.

Contact Information

  • Press Contact:
    Barbara DeConto
    Text 100
    Email Contact

    Investor Relations:
    Geoffrey Plank
    Liolios Group
    Email Contact